相似文献
1
HIV or zidovudine myopathy?
Neurology. 1994 Feb;44(2):360-1; author reply 362-4. doi: 10.1212/wnl.44.2.360-b.
2
HIV or zidovudine myopathy?
Neurology. 1994 Feb;44(2):361-2; author reply 362-4. doi: 10.1212/wnl.44.2.361-b.
3
HIV or zidovudine myopathy?
Neurology. 1994 Feb;44(2):361; author reply 362-4. doi: 10.1212/wnl.44.2.361-a.
4
Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
Neuropathol Appl Neurobiol. 1993 Oct;19(5):406-13. doi: 10.1111/j.1365-2990.1993.tb00462.x.
5
Ultrastructural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies.
Hum Pathol. 1991 Dec;22(12):1281-8. doi: 10.1016/0046-8177(91)90112-3.
6
Zidovudine-associated myopathy.
Am J Hosp Pharm. 1994 Dec 15;51(24):3026-8.
7
HIV or zidovudine myopathy?
Neurology. 1994 Feb;44(2):361; author reply 362-4. doi: 10.1212/wnl.44.2.361.
8
Expression of cytochrome c oxidase subunits encoded by mitochondrial or nuclear DNA in the muscle of patients with zidovudine myopathy.
J Neurol Sci. 1994 Sep;125(2):190-3. doi: 10.1016/0022-510x(94)90034-5.
9
Prognosis in AZT myopathy.
Neurology. 1991 Aug;41(8):1181-4. doi: 10.1212/wnl.41.8.1181.
10
Concurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infection.
Pathology. 1992 Apr;24(2):109-11. doi: 10.3109/00313029209063634.
引用本文的文献
1
Early features of zidovudine-associated myopathy: histopathological findings and clinical correlations.
Acta Neuropathol. 1995;90(1):1-6. doi: 10.1007/BF00294452.
Zotero 插件